Natco Pharma Ltd
Natco Pharma Ltd (NATCOPHARM) last traded at ₹867, a market capitalisation of ₹15,523 crore, on a P/E of 13.6. Over the past 52 weeks the stock has ranged between ₹789 and ₹1,227. Natco Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹735 crore and net profit of ₹206 crore. The next scheduled event is an analyst meet on 27 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Natco Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Natco Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹735 cr, down 44.7% from ₹1,329 cr a year earlier. Net profit was ₹206 cr, down 57.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Expenses | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 |
| Operating profit | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 |
| OPM % | 59% | 8% | 45% | 43% | 42% | 25% | 17% | 25% |
| Other income | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 |
| Interest | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 |
| Depreciation | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 |
| Profit before tax | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 |
| Tax % | 17% | 19% | 20% | 16% | 16% | 13% | -62% | 34% |
| Net profit | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 |
| EPS (₹) | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Natco Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 | 3,485 |
| Operating profit | 606 | 264 | 936 | 1,754 | 2,196 | 1,436 | 1,052 |
| OPM % | 30% | 14% | 35% | 44% | 50% | 35% | 30% |
| Net profit | 442 | 170 | 715 | 1,388 | 1,883 | 1,418 | 1,145 |
| EPS (₹) | 24.18 | 9.31 | 39.18 | 77.51 | 105.26 | 79.20 | 63.89 |
TTM is the trailing twelve months to the most recent quarter.
Natco Pharma Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 15%
- 3 Years
- 15%
- TTM
- -21%
- 10 Years
- 25%
- 5 Years
- 28%
- 3 Years
- 26%
- TTM
- -33%
- 10 Years
- 3%
- 5 Years
- -1%
- 3 Years
- 0%
- 1 Year
- 1%
- 10 Years
- 19%
- 5 Years
- 19%
- 3 Years
- 23%
- Last Year
- 17%
Natco Pharma Ltd shareholding pattern
Promoters held 49.41% at Jun 2026, broadly unchanged since Jun 2025. FIIs 16.99% and DIIs 5.63%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 49.62% | 49.62% | 49.56% | 49.56% | 49.48% | 49.48% | 49.41% | 49.41% |
| FIIs | 17.51% | 17.94% | 17.49% | 15.52% | 14.09% | 15.16% | 17.37% | 16.99% |
| DIIs | 6.75% | 5.59% | 5.64% | 5.81% | 5.87% | 5.39% | 5.46% | 5.63% |
| Public | 26.13% | 26.88% | 27.30% | 29.12% | 30.56% | 29.97% | 27.74% | 27.97% |
| No. of shareholders | 3,02,944 | 3,45,332 | 4,05,222 | 4,29,434 | 4,19,699 | 4,24,167 | 4,10,970 | 4,03,166 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Natco Pharma Ltd events
The next scheduled event is an analyst meet on 27 Aug 2026.
- Analyst meetInvestor meetings organised by Nuvama Wealth Management and ICICI Securities
See the full results calendar for every Indian company reporting in the next 30 days.
Natco Pharma Ltd corporate filings
- Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.Company Updatemedium impact
Cruxal's analysis: Natco Pharma has disclosed a strategic investment in eGenesis, Inc., a biotechnology…
Read the full analysis - Intimation of Investor MeetCompany Updatelow impact
Cruxal's analysis: Natco Pharma has issued an intimation regarding an upcoming investor meet. The filing…
Read the full analysis - Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) UnitCompany Updatelow impact
Cruxal's analysis: Natco Pharma has announced the conclusion of a US FDA inspection at its Finished Dosage…
Read the full analysis - Investor MeetCompany Updatelow impact
Cruxal's analysis: Natco Pharma has issued an intimation regarding an upcoming analyst/investor meet. The…
Read the full analysis - Investor PresentationCompany Updatemedium impact
Cruxal's analysis: Natco Pharma Limited has released its August 2026 investor presentation, highlighting a…
Read the full analysis - Q1FY2026-27 Transcript for the Earnings call held on 14th August, 2026Company Updatemedium impact
Cruxal's analysis: NATCO Pharma reported consolidated revenue of INR794.4 crore for Q1 FY27, down from…
Read the full analysis - Intimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities LimitedCompany Updatelow impact
Cruxal's analysis: Natco Pharma has announced an intimation for investor meetings organized by Nuvama Wealth…
Read the full analysis - Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.Company Updatelow impact
Cruxal's analysis: Natco Pharma Limited has released its unaudited financial results for the quarter ended…
Read the full analysis - Weblink of Audio Transcript for the earnings call held on 14th August, 2026 for Q1FY2026-27Company Updatelow impact
Cruxal's analysis: Natco Pharma Limited has formally disclosed the audio weblink for its Q1 FY26-27 earnings…
Read the full analysis - Investor Presentation for the Q1FY27Company Updatehigh impact
Cruxal's analysis: Natco Pharma Limited reported Q1 FY27 consolidated revenue of 794.4 crore and a net…
Read the full analysis - Board of Directors at their Meeting held on today i.e. 14th August, 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- eachCorp. Actionlow impact
Cruxal's analysis: Natco Pharma Limited has announced an interim dividend of INR 1.50 per equity share (face…
Read the full analysis - Outcome of Board MeetingBoard Meetinghigh impact
Cruxal's analysis: Natco Pharma reported a significant YoY decline in Q1 FY27, with consolidated revenue…
Read the full analysis - The Company will host an Earnings Call with Investors / Analysts on Friday, the 14th August, 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ....Company Updatelow impact
Cruxal's analysis: Natco Pharma Limited has announced that it will host an earnings conference call on…
Read the full analysis - Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Further to our earlier intimation ....Board Meetingmedium impact
Cruxal's analysis: Natco Pharma Limited has formally intimated the stock exchanges regarding a board meeting…
Read the full analysis - Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for ....Board Meetinglow impact
Cruxal's analysis: Natco Pharma Limited has announced a Board of Directors meeting scheduled for 14th August…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Natco Pharma Ltd
Cruxal reads every Natco Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.